Alex Biese

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer.

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 K27M-mutant diffuse glioma, with a target action date of Aug. 18.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally advanced head and neck cancer.

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous leukemia.

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.

The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among patients with gliomas.

From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear-cell renal cell carcinoma.

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

CURE® spoke with experts about what life is like for patients with cancer when their disease is in remission.

An expert spoke with CURE about providers’ “two-fold goal” when using chemotherapy to treat patients with breast cancer.

An expert spoke with CURE® about the emotional bonds that can develop while treating patients with cancer.

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.

CURE spoke with an expert about how psychedelics such as psilocybin may impact patients’ mental health.

An expert explains the new phase of Princess Kate’s cancer journey as she enters remission.

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

From the death of a TikTok influencer to an update from a “Boy Meets World” star, here is this week’s news.

The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received chemotherapy.

The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some patients with MCL.

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

Findings show that 81% of posts related to cancer on the social media platform TikTok touted fake cures.

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.